SubQ Testosterone for Women and Health Recovery

SubQ Testosterone for Women After Auto Accidents

Abstract: After a crash or work injury, recovery is not only about the disc, the neck, or the police report. Energy, muscle, bone, sleep, and desire all shape how well a woman can stay in rehab. Testosterone is not a male-only hormone. Women make it throughout adult life, and levels fall with age. The strongest research supports low-dose therapy for postmenopausal women with distressing low sexual desire. Subcutaneous injections place a small, steady dose into the fat under the skin so blood levels can return to a normal female range. This Personal Injury Doctor Group guide explains how those shots work, who may be a candidate, how the dose is monitored, how muscle and bone support rehab, and how medically integrated chiropractic care in El Paso ties the hormone plan to spinal health, personal-injury recovery, and medical oversight.

Injury Recovery and Hormones Belong in the Same Plan

A rear-end collision, T-bone crash, or lifting injury can leave a woman with whiplash, a herniated disc, delayed neck pain, or hip and shoulder strain. Those injuries are the reason many patients first walk into a personal-injury clinic. What often gets missed is the rest of the picture: fatigue that makes home exercise hard, weaker muscle around an injured spine, thinner bone after menopause, and a loss of desire that adds stress at home while she is still in treatment.

Testosterone is part of that picture. Across most of adult life, a woman’s ovaries and adrenal glands produce more testosterone than estrogen by weight. That output falls with age and drops further if the ovaries are removed (Davis et al., 2019; Hatzilabrou, 2025). Restoring a low level is not a shortcut around chiropractic care, imaging, or rehab. It is one tool that may help the right woman stay strong enough to complete recovery.

At Injury Medical Clinic PA, listed for patients through Personal Injury Doctor Group, care is built for that whole process—acute injury, delayed symptoms, legal documentation, and long-term function—not a single visit.

The One Use With Solid Trial Support

The diagnosis with Level I evidence is hypoactive sexual desire disorder (HSDD) in postmenopausal women. Distress is the key. A quiet fade she accepts differs from a persistent, unwanted loss that troubles her (Davis et al., 2019; Parish et al., 2021).

Pooled randomized trials in thousands of women show that bringing testosterone back into the normal premenopausal range can improve desire, arousal, orgasm, pleasure, and satisfaction and can lower sexual distress. The benefit is real and consistent, but moderate. A strong placebo response is part of the data, so honest counseling matters (Islam et al., 2019; Hatzilabrou, 2025).

Other reasons people ask about testosterone—low mood, brain fog, general energy—have mixed or weaker evidence. Societies do not list those as stand-alone indications. Bone density rose in one small implant trial when testosterone was added to estradiol, but that study was not built to prevent fractures (Davis et al., 1995; Wierman et al., 2014).

For a personal-injury patient, the honest frame is this: treat the proven indication carefully, and treat the crash, the disc, and the weak core at the same time.

How Subcutaneous Testosterone Injections Work

A subcutaneous (SubQ) shot goes into the fatty layer just under the skin, not deep into muscle. Common sites are the belly or outer thigh. The needle is short and thin. Testosterone cypionate in oil then seeps out slowly, which can keep blood levels steadier than a large intramuscular injection (FOLX Health, n.d.; Hone Health, 2024).

Women need far less than men—often about one-tenth of a typical male dose. Clinics that use weekly SubQ cypionate usually start low and change the milligrams only after a lab result, not after a single “I feel tired” day (Highland Longevity, n.d.).

Keep these route facts clear:

• Most high-quality trials in women used patches, creams, or gels, not weekly shots (Hatzilabrou, 2025).
• One older implant study in women was positive for desire and bone density. Fixed pellets can overshoot the female range and cannot be turned down once placed (Hatzilabrou, 2025).
• No published milligram conversion exists from a 300-microgram patch to a SubQ syringe. The dose is based on a measured blood level (Davis et al., 2019).
• No testosterone product is FDA-approved for women in the United States. Use is off-label and needs informed consent (Cedars-Sinai, n.d.; Parish et al., 2021).

Some compounding programs offer low-concentration, prefilled single-dose syringes of testosterone cypionate in MCT oil for SubQ use. A ready syringe does not change the rules. Exposure still has to stay inside the female physiologic band (Hatzilabrou, 2025; Medivant Health, n.d.).

Dose to a Range, Not Past It

A healthy young woman often carries a total testosterone of about 15 to 46 ng/dL. That is a sliver of the male range. The job of therapy is to land in that band and stay there (Hatzilabrou, 2025; Braunstein et al., 2011).

Going higher does not add extra desire. It is how acne, extra facial hair, scalp thinning, and, rarely, voice change appear (Islam et al., 2019).

A practical pathway looks like this:

• Confirm distressing low desire after checking relationship strain, mood, sleep, pain with intercourse, and medicines that blunt desire (SSRIs above all).
• Draw baseline total testosterone with a sensitive LC-MS/MS test (Rosner et al., 2007).
• Start low.
• Recheck the level and symptoms at about 8 to 12 weeks.
• Judge benefit at 3 to 6 months. If distressing low desire has not improved, stop rather than climb (Davis et al., 2019; Parish et al., 2021).

The number does not diagnose HSDD. It is a safety tool once treatment starts. After a motor-vehicle accident, treat genitourinary pain and pelvic-floor tension first if they are the real reason sex hurts. Local estrogen, not a systemic androgen, is built for that problem (Parish et al., 2021).

Why Muscle, Bone, and Rehab Matter After an Injury

Even when desire is the proven target, the body effects matter in a personal-injury clinic.

Muscle. Testosterone supports muscle protein building. Some women notice a better training response when levels return to a mid-physiologic range. Large pooled trial data at HSDD doses have not shown a strong body-composition effect, so this is possible support, not a promise (Islam et al., 2019; Hatzilabrou, 2025).

Bone. Better bone quality helps the vertebrae absorb crash and adjustment forces. One small trial found faster density gains when testosterone was added to estradiol; guidelines still do not list bone as an approved reason to prescribe (Davis et al., 1995; Wierman et al., 2014).

Energy for the plan. Rehab after whiplash or a work injury asks a woman to show up, move, and rebuild. If she cannot complete core work, spinal decompression, or gait training, the mechanical plan stalls. Hormone care does not replace those visits. It may make the visits usable.

Clinical observation from Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, is consistent with that caution: female testosterone use is not a copy of male replacement. The strongest randomized evidence is still transdermal. SubQ use in women is an individualized, off-label choice. The goal is a physiologic range with a stop rule if desire does not improve (Jimenez, n.d.-b).

Safety While a Case Is Still Open

Short-term data at physiologic doses are generally reassuring for day-to-day effects: acne, extra hair, and oily skin. Those effects are usually dose-related and often fade if the dose is cut (Islam et al., 2019; Nachtigall et al., 2011).

Long-term cardiovascular and breast outcomes over many years remain unsettled in large trials. That gap is a main reason no female product has been approved (Hatzilabrou, 2025; Cedars-Sinai, n.d.).

Therapy is not for pregnancy, breastfeeding, or people trying to conceive. Women with high baseline heart or breast-cancer risk need a clear shared decision, documented in the chart—the same way injury findings, imaging, and work status are documented in a personal-injury file (Hone Health Help Center, n.d.).

Medically Integrated Care in El Paso

Hormones do not float apart from the skeleton. Low energy, weaker muscles, and slower recovery can stiffen spinal joints and make auto-accident rehab harder.

Personal Injury Doctor Group presents El Paso’s medically integrated personal-injury model at Injury Medical Clinic PA (Mission Plaza), 11860 Vista Del Sol, Suite 128, with rehabilitation support at 6440 Gateway East, Suite B, and 7100 Airport Blvd, Suite C.

Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, is dual-licensed as a chiropractor and board-certified family nurse practitioner. He focuses on spinal alignment, neuromusculoskeletal function, personal-injury care plans, functional medicine, and the full recovery process after auto and work injuries (Jimenez, n.d.-a).

Working with him is Dr. Maria Guadalupe Cardenas, MD, board-certified in internal medicine (NPI #1164426749, Texas MD License #J2933), with more than 40 years of experience as an internist. She serves as medical director and collaborative physician. In this setup—common in strong integrative injury clinics—the internist provides medical direction, reviews labs and overall health, and helps keep off-label therapies inside safe bounds. The chiropractor restores joint motion, posture, and muscle control. Rehab rebuilds strength after crashes. Functional medicine looks at sleep, gut health, thyroid, iron, and medicines that can blunt desire on their own.

That is how a woman after a collision can have one coordinated plan: image the spine, document delayed symptoms for the injury case, adjust and decompress when indicated, train the hips and core, and, if she meets the HSDD criteria, consider low-dose testosterone under medical oversight instead of treating the hormone as a stand-alone wellness shot.

A Clear Next Step

Testosterone therapy in women is not a male protocol scaled down by guesswork. It is a narrow option for postmenopausal HSDD with distress, given at a female physiologic dose, watched with the right lab, and stopped if it does not help.

Subcutaneous injections can deliver that small, steady dose into the fat under the skin. They still ask for discipline: start low, measure, stay inside the range, and pair the hormone with injury care—local treatment when dryness is the real problem, medication review when an antidepressant is the real problem, and hands-on musculoskeletal care when the spine and hips cannot carry the load.

If you are recovering from an auto accident or work injury in El Paso and also struggling with distressing low desire, energy for rehab, or strength around an injured spine, ask for a full evaluation. Call the office at 915-850-0900 or 915-412-6677, or reach Dr. Jimenez at 915-540-8444. You can also start through Personal Injury Doctor Group and the clinic’s online intake and appointment links.

---

References

Braunstein, G. D., Reitz, R. E., Buch, A., Schaefer, D., & Caulfield, M. P. (2011). Testosterone reference ranges in normally cycling healthy premenopausal women. The Journal of Sexual Medicine, 8(10), 2924–2934.

Cedars-Sinai. (n.d.). Testosterone therapy for women.

Davis, S. R., Baber, R., Panay, N., Bitzer, J., Perez, S. C., Nappi, R. E., Nijland, E., Simon, J., Vignozzi, L., & Wierman, M. E. (2019). Global consensus position statement on the use of testosterone therapy for women. The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666.

Davis, S. R., McCloud, P., Strauss, B. J., & Burger, H. (1995). Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas, 21(3), 227–236.

FOLX Health. (n.d.). HRT subcutaneous vs. intramuscular injections.

Hatzilabrou, T. A. (2025). Testosterone therapy in women [White paper]. Worldborne Medical / Medivant Healthcare.

Highland Longevity. (n.d.). Women’s testosterone dosing guide.

Hone Health. (2024). Injectable testosterone cypionate for women.

Hone Health Help Center. (n.d.). Testosterone cypionate injection for women: Risks & benefits.

Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019). Safety and efficacy of testosterone for women: A systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes & Endocrinology, 7(10), 754–766.

Jimenez, A. (n.d.-a). Injury specialists. Personal Injury Doctor Group / Injury Medical Clinic PA.

Jimenez, A. (n.d.-b). Subcutaneous testosterone for hormone balance therapy guide. Injury Medical Clinic PA.

Medivant Health. (n.d.). Andrenyx.

Nachtigall, L., Casson, P., Lucas, J., Schofield, V., Melson, C., & Simon, J. A. (2011). Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecological Endocrinology, 27(1), 39–48.

Parish, S. J., Simon, J. A., Davis, S. R., Giraldi, A., Goldstein, I., Goldstein, S. W., Kim, N. N., Kingsberg, S. A., Morgentaler, A., Nappi, R. E., Park, K., Stuenkel, C. A., Traish, A. M., & Vignozzi, L. (2021). International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. The Journal of Sexual Medicine, 18(5), 849–867.

Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007). Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. The Journal of Clinical Endocrinology & Metabolism, 92(2), 405–413.

Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N. (2014). Androgen therapy in women: A reappraisal. An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3489–3510.